Revenue: As of FY2025 Q3, the actual value is USD 45.25 M, beating the estimate of USD 0.EPS: As of FY2025 Q3, the actual value is USD 1.07, beating the estimate of USD -0.12.EBIT: As of FY2025 Q3, the actual value is USD 43.81 M.<h3>Segment Revenue</h3><ul><li>Collaboration Revenues: $45.3 million for the three months ended September 30, 2025, compared to $3.4 million for the same period in 2024. For the nine months ended September 30, 2025, collaboration revenues were $49.0 million, compared to $16.0 million for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Research and Development Expenses: $0.2 million for the three months ended September 30, 2025, compared to $11.3 million for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $11.8 million, compared to $44.1 million for the same period in 2024.</li><li>General and Administrative Expenses: $1.2 million for the three months ended September 30, 2025, compared to $5.2 million for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $8.5 million, compared to $16.2 million for the same period in 2024.</li><li>Net Income (Loss): Net income of $44.7 million for the three months ended September 30, 2025, compared to a net loss of $12.7 million for the same period in 2024. For the nine months ended September 30, 2025, net income was $25.7 million, compared to a net loss of $42.8 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was - $14.1 million for the nine months ended September 30, 2025, compared to - $51.6 million for the same period in 2024.</li><li>Investing Cash Flow: Net cash provided by investing activities was $0.7 million for the nine months ended September 30, 2025, compared to - $0.1 million for the same period in 2024.</li><li>Financing Cash Flow: Net cash used in financing activities was - $1.8 million for the nine months ended September 30, 2025, compared to $1.0 million provided by financing activities for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Deferred Revenue: The remaining balance of deferred revenue related to the Moderna License Agreement was recognized during the three and nine months ended September 30, 2025.</li><li>Termination Fee and Expense Reimbursement: The company recorded a receivable of $1.3 million for the Termination Fee and Expense Reimbursement related to the termination of the Merger Agreement with OrthoCellix.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company has no intention of resuming its historical research and development activities. It expects to continue to attempt to sell or otherwise dispose of or monetize its remaining assets and pursue an orderly wind down of its remaining operations.</li><li>Non-Core Business: The company is pursuing additional asset monetization transactions and has entered into agreements such as the Patent Purchase Agreement with Resolution Therapeutics Limited and the First Amendment to the Collaboration and License Agreement with Moderna.</li><li>Priority: The company is focused on preserving its existing cash resources and maximizing value through strategic alternatives, including the potential wind down of its business.</li></ul>

Carisma Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 45.25 M